Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, highlights a presentation at the ACG Annual ...

FDA on Wednesday restricted the use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) due to the risk of serious liver injury in patients with advanced cirrhosis. Serious side effects ...

Please provide your email address to receive an email when new articles are posted on . In a cohort of predominantly men with primary biliary cholangitis with cirrhosis, ursodeoxycholic acid response ...

This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major ...

Primary biliary cholangitis (PBC), previously referred to as primary biliary cirrhosis, is an autoimmune disorder characterized by intrahepatic cholestasis. While the precise etiology and pathogenesis ...

It is unclear what role treatment plays in affecting hepatocellular carcinoma (HCC) risk, the authors found. The authors wrote about the latest evidence related to the risks and outcomes of HCC in ...

WASHINGTON, DC — Measures of liver stiffness remained stable or improved in patients with primary biliary cholangitis (PBC) after 36 months of treatment with seladelpar (Livdelzi) based on new data ...

Primary biliary cirrhosis (PBC) is a chronic cholestatic disorder that potentially leads to end-stage liver disease. It has an autoimmune component: patients have high serum levels of ...

—A Danish cohort study found higher levels of the inflammation marker SCD163 were associated with lower quality of life in primary biliary cholangitis patients. Patients with primary biliary ...

S ince there’s no cure for primary biliary cholangitis (PBC), the main treatment goal is to slow disease progression and ease symptoms, such as itching. The good news is that, for most people, the ...

Ursodeoxycholic acid (UDCA) is the only drug approved for treating primary biliary cirrhosis, but recent meta-analyses have cast doubt on its long-term benefits. Corpechot and colleagues have examined ...